Minocycline

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Minocycline

Examples of brand names: Klinomycin [DE]

ATC code: J01AA08

Main use (for orientation): Bacterial infections

Documented research summary

Minocycline after repeated THC administration reduced microglial activation and motor/learning deficits in mice. CB1 downregulation persisted; acute withdrawal symptoms were not generally prevented. No clinical combination recommendation.

Uncertainties and limitations

Minocycline began 1 hour after the final THC dose and continued for 5 days. Withdrawal/knockout model, not routine human co-medication. Missing data do not establish safety.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC – laboratory and animal studies

Finding ID: B0449

Type of result: Pharmacodynamics; intervention in a withdrawal/microglial model

Observation: Minocycline reduced microglial activation and cerebellar learning/motor deficits; CB1 downregulation itself persisted.

Mechanism: Inhibition of microglial activation after THC-associated CB1 downregulation

Study type: Mouse experiment after repeated THC exposure

Context studied: Minocycline 40 mg/kg intraperitoneally, starting 1 hour after the final THC dose and then daily for 5 days; mouse model, not human dosage.

Clinical interpretation: Mechanistic hypothesis, not a recommendation for cannabis-withdrawal or combination therapy.

Limitations and uncertainties: No human drug interaction; acute minocycline did not generally prevent withdrawal symptoms. Controlled specialised models including CB1 knockout.

Original sources for this finding: Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. [VE_MED_23934130]

References and access status

[VE_LABEL_D0289] MINOCIN (MINOCYCLINE HYDROCHLORIDE) INJECTION [MELINTA THERAPEUTICS, LLC]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2025

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VE_MED_23934130] Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure.

Original source / bibliographic reference

Authors: Cutando L, Busquets-Garcia A, Puighermanal E, Gomis-González M, Delgado-García JM, Gruart A, Maldonado R, Ozaita A.

Year: 2013

Source type: Research Support, Non-U.S. Gov't; research-article; Journal Article

DOI: 10.1172/jci67569

PMID: 23934130

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility